New discoveries in the basic science understanding of Peyronie’s disease
Author:
Publisher
Springer Science and Business Media LLC
Subject
Urology,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s11934-004-0074-y.pdf
Reference51 articles.
1. de La Peyronie F: Sur Quelsques obstacles qui s’opposent a l’ejaculation naturelle de la semance. Med Aca R Chir 1743, 1:425.
2. Lindsay MB, Schain DM, Grambsch P, et al.: The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991, 146:1007–1009.
3. Schwarzer U, Sommer F, Klotz T, et al.: The prevalence of Peyronie’s disease: results of a large survey. BJU Int 2001, 88:727–730.
4. Mulhall JP, Creech SD, Boorjian SA, et al.: Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol 2004, 171:2350–2353.
5. Kadioglu A, Oktar T, Kandirali E, et al.: Incidentally diagnosed Peyronie’s disease in men presenting with erectile dysfunction. Int J Impot Res 2004 [Epub head of print].
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. TGF-β1 induces formation of TSG-6-enriched extracellular vesicles in fibroblasts which can prevent myofibroblast transformation by modulating Erk1/2 phosphorylation;Scientific Reports;2024-05-29
2. European Society of Sexual Medicine consensus statement on the use of animal models for studying Peyronie’s disease;Sexual Medicine;2023-08-01
3. Statins synergize with phosphodiesterase type 5 inhibitors but not with selective estrogen receptor modulators to prevent myofibroblast transformation in an in vitro model of Peyronie’s disease;The Journal of Sexual Medicine;2023-04-20
4. Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie’s disease;PLOS ONE;2022-12-12
5. Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie's Disease;The Journal of Sexual Medicine;2020-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3